CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lower urinary tract symptoms in men, age-related (including symptoms of benign prostatic hyperplasia/hypertrophy) - Management
View full scenario no prescriptions
How do I manage a man with overactive bladder as the predominant symptom?
- Exclude or manage treatable causes of overactive bladder (for example cancer of the prostate or bladder, neurological conditions, infection, and bladder stones).
- Investigations to exclude treatable causes of an overactive bladder include urinalysis, renal function tests, and (depending on the clinical features) PSA (prostate specific antigen) level.
- It is often not possible to identify a specific underlying cause.
- If necessary, offer a choice of temporary urine containment products (such as sheath and leg bag, absorbent pads, and absorbent pants) to achieve social continence, and refer the man to the local continence service.
- To find the local continence service, telephone the Bowel and Bladder Foundation on 01536 533 255.
- Offer referral for supervised bladder training — this may be available from the local continence nurse, continence physiotherapist, or urology clinic.
- Advise the man on fluid intake and lifestyle, and offer information on self-help resources.
- If bothersome symptoms persist, offer an antimuscarinic (anticholinergic).
- For example oxybutynin — initially 5 mg two to three times daily, increased if necessary to a maximum of 5 mg four times daily. Elderly men require lower doses.
- For full prescribing information and choice of antimuscarinic drug, see Antimuscarinics for overactive bladder.
- Review every 4–6 weeks until symptoms are stable, and then every 6–12 months. Assess symptoms, quality-of-life, adverse effects, and the need to continue treatment.
- If treatment fails, refer the man for specialist urological assessment and management.
- Treatment options in secondary care include injection of botulinum into the bladder wall, implanted sacral nerve stimulation, and cystoplasty.
Basis for recommendation
These recommendations are in line with the guideline The management of lower urinary tract symptoms in men from the National Institute for Health and Clinical Excellence (NICE) [NICE, 2010].
Supervised bladder training, advice on fluid intake, lifestyle advice, containment products
- The recommendations on supervised bladder training, advice on fluid intake, lifestyle advice, and containment products are based on expert opinion, as NICE found no relevant clinical or economic studies [NICE, 2010].
Antimuscarinics (anticholinergics)
- The recommendation to consider using an antimuscarinic for overactive bladder symptoms is based on expert opinion. The best trial-based evidence is from one small randomized controlled trial, which reported the data graphically and without statistical analysis [NICE, 2010].
- Anticholinergics reduced the number of urinary incontinence episodes compared with placebo (but not compared with alpha-blockers). There were no other improvements noted compared with placebo. Reduction in the number of incontinence episodes is an important benefit.
- Minor adverse effects (such as dry mouth) are common. Urinary retention is a serious possible adverse effect, but NICE found no evidence that this risk is clinically important.
- The recommendations on follow up and monitoring are based on expert opinion, as NICE found no relevant clinical trials.
Secondary care treatments
- The information on treatments used in secondary care is from the NICE guidance [NICE, 2010].
What advice should I provide about self-help resources?
- Advise that:
- The Bladder and Bowel Foundation have a helpline (telephone 01536 533 255), and provide a range of resources on their website www.bladderandbowelfoundation.org, which include:
- A booklet on coping with urgency — this can be ordered from their online shop or downloaded for printing (pdf). The booklet includes detailed information on bladder retraining.
- A Just Can't Wait toilet card to use when the need to urinate arises while out shopping or socializing. Most shops and facilities are willing to help when they are shown the card. A small donation is requested to cover costs.
Basis for recommendation
These recommendations are in line with the guideline The management of lower urinary tract symptoms in men from the National Institute for Health and Clinical Excellence (NICE) [NICE, 2010].
- NICE recommends providing men with lower urinary tract symptoms with information and advice on the basis of expert opinion, as they found no relevant clinical trials [NICE, 2010].
What self-care advice should I provide about fluid intake and lifestyle for men with lower urinary tract symptoms?
- Fluid intake should be within the man's usual range, and should not be limited excessively in an attempt to control symptoms — doing this could increase the risk of complications such as urinary tract infection.
- Lifestyle advice may include:
- Avoiding constipation, or treating it (if it is present).
- Maintaining a healthy lifestyle (with respect to body weight, exercise, diet, smoking, and alcohol consumption).
- Limiting intake of tea, coffee, chocolate, artificial sweeteners, and fizzy drinks.
Basis for recommendation
These recommendations are in line with the guideline The management of lower urinary tract symptoms in men from the National Institute for Health and Clinical Excellence (NICE) [NICE, 2010].
- NICE based these recommendations on expert opinion as they found no relevant clinical trials [NICE, 2010].
Prescriptions
For information on contraindications, cautions, drug interactions, and adverse effects, see the electronic Medicines Compendium (eMC) (http://emc.medicines.org.uk), or the British National Formulary (BNF) (www.bnf.org).
First-line antimuscarinic: oxybutynin
Age from 40 years onwards
Start oxybutynin tablets: 5mg two to three times a day
Oxybutynin 5mg tablets
Take one tablet two to three times a day.
Supply 56 tablets.
Age from 60 years onwards
Start oxybutynin tablets (elderly): 2.5mg twice a day
Oxybutynin 2.5mg tablets
Take one tablet twice a day.
Supply 56 tablets.
Start oxybutynin tablets (elderly): 3mg twice a day
Oxybutynin 3mg tablets
Take one tablet twice a day.
Supply 56 tablets.
Second-line antimuscarinics: if oxybutynin not tolerated
Age from 40 years onwards
Start oxybutynin m/r tablets: 5mg once a day
Oxybutynin 5mg modified-release tablets
Take one tablet once a day.
Supply 30 tablets.
Start oxybutynin patches: apply one patch twice a WEEK
Oxybutynin 3.9mg/24hours patches
Apply one patch twice a week.
Supply 8 patches.
Start tolterodine m/r capsules: 4mg once a day
Tolterodine 4mg modified-release capsules
Take one capsule once a day.
Supply 28 capsules.
Start tolterodine tablets: 2mg twice a day
Tolterodine 2mg tablets
Take one tablet twice a day.
Supply 56 tablets.
Start trospium tablets: 20mg twice a day
Trospium chloride 20mg tablets
Take one tablet twice a day (on an empty stomach).
Supply 60 tablets.
Start trospium m/r capsules: 60mg once a day
Trospium chloride 60mg modified-release capsules
Take one capsule once a day.
Supply 28 capsules.
Start darifenacin m/r tablets: 7.5mg once a day
Darifenacin 7.5mg modified-release tablets
Take one tablet once a day.
Supply 28 tablets.
Start fesoterodine m/r tablets: 4mg once a day
Fesoterodine 4mg modified-release tablets
Take one tablet once a day.
Supply 28 tablets.
Start solifenacin tablets: 5mg once a day
Solifenacin 5mg tablets
Take one tablet once a day.
Supply 28 tablets.
Start propiverine tablets: 15mg 2 to 3 times a day
Propiverine 15mg tablets
Take one tablet two to three times a day.
Supply 84 tablets.
Start propiverine m/r capsules: 30mg once a day
Propiverine 30mg modified-release capsules
Take one capsule once a day.
Supply 28 capsules.
© NHS Institute for Innovation and Improvement